80 likes | 257 Views
REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH. FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Senior Associate Commissioner for Science. FDA REGULATES. 20 percent of the consumer purchases $50 billion of medical R&D 8 million import shipments/year
E N D
REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Senior Associate Commissioner for Science Nanotechnology - USDA - 18 Nov 2002
FDA REGULATES • 20 percent of the consumer purchases • $50 billion of medical R&D • 8 million import shipments/year • Food, drugs, biologicals, devices, cosmetics, blood • Counter terrorism products Nanotechnology - USDA - 18 Nov 2002
FDA’S PUBLIC HEALTH MISSION • Safety • Efficacy • Good Manufacturing controls • Risk analysis • Be a force in counter-terrorism Nanotechnology - USDA - 18 Nov 2002
FDA ORGANIZATION • Center for Biologics Evaluation and Research • Center Drug Evaluation and Research • Center for Devices and Radiological Health • Center for Food Safety and Applied Nutrition • Center for Veterinary Medicine • Office of Regional Operations • National Center for Toxicological Research Nanotechnology - USDA - 18 Nov 2002
PUBLIC HEALTH IMPLICATIONS FOR NANOTECHNOLOGY • New materials and manufacturing processes • All FDA regulated areas are likely affected • drugs, medical devices, biologicals, food • The science is new to the Agency • Risk management is our job • Education of the Public will define its acceptance Nanotechnology - USDA - 18 Nov 2002
NATIONAL NANOTECHNOLOGY INITIATIVE • Examples of fundamental research that will be regulated by FDA • Biological assembly of nanostructures • Using DNA molecules to construct nanoscale devices • Artificial genetic system • Modeling and simulation of biological ion channels to cure diseases • Nanoscale film serves as molecular filter Nanotechnology - USDA - 18 Nov 2002
NANOTECHNOLOGY AND COMMERCIALIZATION OF PUBLIC HEALTH PRODUCTS • Education & training of FDA • Education of the Public – Developing the public perception • Education and training of industry sectors unfamiliar with FDA • Demonstrate the safety of products • Demonstrate the efficacy of products • Establishment of standards of manufacturing, performance, and approval • Risk analysis and management Nanotechnology - USDA - 18 Nov 2002
CHALLENGES!! • New technology – Unknown risks • Education – A bad job here can minimize the utility • Stakeholder involvement • Early involvement of all parties • Risk communication • FDA guidance development – Help us. Nanotechnology - USDA - 18 Nov 2002